KNSA Kiniksa Pharmaceuticals (KNSA) Q4 FY25 earnings call
Kiniksa Pharmaceuticals delivered robust Q4 and full-year 2025 results, driven by strong ARCALYST revenue growth and expanding adoption in recurrent pericarditis. The company achieved profitability and significant cash generation, enabling continued investment in its commercial infrastructure and advancing its clinical pipeline with KPL-387 and KPL-1161. Management is focused on unlocking the next phase of ARCALYST growth through increased physician awareness and digital marketing, while also preparing for future market expansion with its pipeline assets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
KNSA operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Prescribers | 4,150+At the end of 2025, more than 4,150 prescribers had written a prescription for ARCALYST.Source: earnings call transcript | — | 5,000+Approximately 450 additional health care professionals wrote their first ARCALYST prescription in the second quarter, bringing the total prescriber base to more than 5,000 launch to date.Source: earnings call transcript | — |
| Repeat prescribers | 1,200+Of those, around 29% or more than 1,200 prescribers have written ARCALYST for 2 or more recurrent pericarditis patients.Source: earnings call transcript | ~1,320We also saw growth in the number of health care professionals who became repeat prescribers during Q1, resulting in approximately 1,320 prescribers in total who have now prescribed ARCALYST multiple times.Source: earnings call transcript | — | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.